AI assistant
Sending…
Ovid Therapeutics Inc. — Director's Dealing 2018
Jun 8, 2018
34195_dirs_2018-06-08_ed9c4988-b9ff-4057-8520-40dfb644329a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Ovid Therapeutics Inc. (OVID)
CIK: 0001636651
Period of Report: 2018-06-07
Reporting Person: Duncan Barbara Gayle (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-06-07 | Stock Option (Right to Buy) | $8.12 | A | 5813 | Acquired | 2028-06-06 | Common Stock (5813) | Direct |
Footnotes
F1: The option will vest in full on June 7, 2019, subject to the Reporting Person's continuous service through such vesting date.
More from Ovid Therapeutics Inc.
Board/Management Information
2026
Jun 3
Interim / Quarterly Report
2026
May 12
Report Publication Announcement
2026
May 12
Annual Report
2026
Apr 27
Proxy Solicitation & Information Statement
2026
Apr 27
Capital/Financing Update
2026
Apr 27
Capital/Financing Update
2026
Apr 20
Director's Dealing
2026
Mar 26
Annual Report
2026
Mar 18
Director's Dealing
2026
Mar 2